Istanbul University-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2022

  1. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

    JTO Clinical and Research Reports, Vol. 3, Núm. 6

2021

  1. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

2020

  1. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 6, pp. 1002-1009

  2. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

2019

  1. Equalization of four cardiovascular risk algorithms after systematic recalibration: Individual-participant meta-analysis of 86 prospective studies

    European Heart Journal, Vol. 40, Núm. 7, pp. 621-631

2018

  1. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    The Lancet, Vol. 392, Núm. 10142, pp. 123-133

2017

  1. Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort (Pediatr Nephrol, 10.1007/s00467-016-3469-3)

    Pediatric Nephrology

  2. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort

    Pediatric Nephrology, Vol. 32, Núm. 1, pp. 139-150

  3. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218

  4. Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis

    American Journal of Epidemiology, Vol. 186, Núm. 8, pp. 899-907

2016

  1. Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care

    Current Opinion in Neurology

  2. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients

    Nephrology Dialysis Transplantation, Vol. 31, Núm. 6, pp. 1002-1013

2015

  1. Renal replacement therapy in Europe: A summary of the 2012 ERA-EDTA Registry Annual Report

    Clinical Kidney Journal, Vol. 8, Núm. 3, pp. 248-261

2014

  1. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey

    Seminars in Arthritis and Rheumatism, Vol. 43, Núm. 5, pp. 666-672

  2. Glycated hemoglobin measurement and prediction of cardiovascular disease

    JAMA - Journal of the American Medical Association, Vol. 311, Núm. 12, pp. 1225-1233

2013

  1. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1747-1755

  2. 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Arthritis and Rheumatism, Vol. 65, Núm. 11, pp. 2737-2747

2012

  1. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

    European Journal of Cancer, Vol. 48, Núm. 3, pp. 324-332

  2. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise

    Arthritis Care and Research, Vol. 64, Núm. 3, pp. 351-357